Eric Sherman

20PUBLICATIONS
86CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Oct 01, 2024
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma.

Antoine Desilets, Joris L Vos, Nora Katabi

|Jun 26, 2024
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.

Jena D French, Bryan R Haugen, Francis P Worden

|Jan 19, 2024
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.

Nancy Y Lee, Eric J Sherman, HeiKo Schöder

|Jul 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).

Alan L Ho, Nathan R Foster, Alex J Zoroufy

|Jun 15, 2022
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase.

Laura Boucai, Federico Salas-Lucia, Gnana P Krishnamoorthy

Pageof 4

Frequent Collaborators

4 joint publications

Nancy Y Lee

4 joint publications

Luc G T Morris

4 joint publications

Nadeem Riaz

4 joint publications

Alan L Ho